FreeTheAI

Seaport Therapeutics, Inc.

SPTX · NASDAQ · USD

$18.15

+0.24 1.34%todayNot financial advice.

SPTX Price chart 1M
Open
18.00
Day range
17.89 - 18.79
52-week range
14.85 - 28.38
Volume
171.21K
Market cap
971.58M
P/E ratio
—
EPS
—
Dividend yield
0.00%
Beta
0.65

Performance

W

−5.27%

1M

−24.81%

3M

−11.76%

6M

−5.32%

YTD

−5.32%

Y

−5.32%

5Y

−5.32%

All

−5.32%

In the news

  1. Oct 9

    Seaport Therapeutics Presents Positive Phase 1 Trial Data for Anxiety Drug

    Seaport Therapeutics announced Phase 1 clinical trial data for anxiety drug candidate GlyphAgo, showing improved bioavailability and lower liver exposure.

    Company news

  2. Oct 9

    Seaport Therapeutics Reports Positive Phase 1 Trial Results for Anxiety Drug GlyphAgo

    Seaport Therapeutics (SPTX) reported strong Phase 1 data for GlyphAgo, showing improved absorption. A Phase 2/3 trial is planned for early 2027.

    Company news

  3. Oct 9

    PureTech and Seaport Present Phase 1 Data for Experimental Anxiety Therapy

    Seaport Therapeutics presented early-stage clinical data for GlyphAgo, a treatment designed to target anxiety with fewer liver side effects.

    Company news

  4. Oct 9

    Seaport Therapeutics Presents Phase 1 Data for Anxiety Drug GlyphAgo

    Seaport Therapeutics presented Phase 1 data for its anxiety drug GlyphAgo, showing improved absorption and lower liver risks than standard treatments.

    Company news

  5. Oct 9

    Seaport Therapeutics Shares Phase 1 Data for Anxiety Drug Candidate GlyphAgo

    Seaport Therapeutics reported positive Phase 1 data for its drug candidate GlyphAgo, showing improved absorption and lower variability.

    Company news

  6. Oct 7

    Seaport Therapeutics Doses First Patient in Phase 2a Trial for Anxiety Treatment

    Seaport Therapeutics has dosed the first patient in a Phase 2a trial of GlyphAgo for generalized anxiety disorder and sleep disturbance.

    Company news

  7. Oct 7

    Seaport Therapeutics Starts Phase 2a Trial of Anxiety Drug GlyphAgo

    Seaport Therapeutics has dosed the first patient in a Phase 2a trial of GlyphAgo, an anxiety drug designed to reduce liver toxicity and improve sleep.

    Company news

Embed on your site

Embed docs

Add a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.

<iframe src="https://stocks.freetheai.org/embed/NASDAQ-SPTX" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="Seaport Therapeutics, Inc. (SPTX) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/NASDAQ-SPTX">SPTX stock price</a> by FreeTheAI Stocks</p>